Clinical trial data with orforglipron have shown no signal for thyroid C-cell pathology or MTC
Summer Kessel is a Registered Dietitian and Certified Specialist in Obesity and Weight Management
Z.MengJ.WuX
Regulatory Frameworks and Supply Dynamics: In December 2025, the FDA approved the first oral GLP-1 for weight loss-Novo Nordisk's once-daily semaglutide pill, which launched in January 2026, significantly expanding accessibility for patients averse to injections [3]
Before taking liraglutide injection tell your healthcare provider about all of your medical conditions, including if you: have or have had problems with your pancreas have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food
If an individual has Type 2 Diabetes with established cardiovascular disease, GLP-1 Receptor Agonists can lower the risk of heart attacks, stroke, and cardiovascular death